The effect of exogenous activation of protease-activated receptor 2 on cutaneous vasodilatation and sweating in young males during rest and exercise in the heat. Issue 3 (3rd July 2018)

• Record Type: Journal Article
• Authors: Fujii, Naoto; Danquah, Mercy O.; Meade, Robert D.; Nishiyasu, Takeshi; Kenny, Glen P.
• Is Part Of: Temperature. Volume 5:Issue 3(2018)
• Page Start: 257
• Page End: 266
• Publication Date: 2018-07-03
• Subjects: Trypsin -- serine protease -- inflammation -- heat loss responses -- microcirculation; Thermobiology -- Periodicals; Thermotherapy -- Periodicals; Body temperature -- Regulation -- Periodicals; Body temperature -- Regulation; Thermobiology; Thermotherapy; Periodicals; 571.46
• DOI: 10.1080/23328940.2018.1506563
• Languages: English
• ISSNs: 2332-8940

Abstract

ABSTRACT: Protease-activated receptor 2 (PAR2) exists in the endothelial cells of skin vessels and eccrine sweat glands. We evaluated the hypothesis that exogeneous activation of PAR2 augments cutaneous vasodilatation and sweating during rest and exercise in the heat. In 10 young males (23 ± 5 y), cutaneous vascular conductance (CVC) and sweat rate were measured at four forearm skin sites treated with either 1) lactated Ringer (Control), 2) 0.05 mM, 3) 0.5 mM, or 4) 5 mM SLIGKV-NH2 (PAR2 agonist). Participants initially rested in a semi-recumbent posture under a normothermic ambient condition (25°C) for ~60 min. Thereafter, ambient temperature was increased to 35°C while the participants rested for an additional 60 min. Participants then performed a 50-min bout of cycling (~55% of their pre-determined peak oxygen uptake) followed by a 30-min recovery period. Administration of 5 mM SLIGKV-NH2 increased cutaneous vascular conductance relative to the Control site during normothermic resting (P ≤ 0.05). However, we showed that relative to the Control site, no effect on CVC was observed for any administered dose of SLIGKV-NH2 (0.05-5 mM) during rest (33–39%max CVC), end-exercise (68–70%max CVC), and postexercise recovery (49–53%max CVC) in the heat (all P > 0.05). There were no differences in sweat rate between the Control and all SLIGKV-NH2 -treated sites throughout the protocol (0.21–0.23, 1.20–1.27, and 0.32–0.33 mg∙min −1 ∙cm −2 for rest, end-exercise, and postexercise in the heat, respectively, all P > 0.05). We show that while exogeneous PAR2 activation induces cutaneous vasodilatation during normothermic rest, it does not influence the cutaneous blood flow and sweating responses during rest, exercise or recovery in the heat.